H. T. See - Concepedia

Author

H. T. See

The University of Texas MD Anderson Cancer Center

Also Known As

H See, H T See, H. See, H. T. See, H.T See, H.T. SEE, H.T. See, Heidi See, Hui Ti SEE, Hui Ti See

Publications

390

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center National Cancer Centre Singapore

About

H. T. See is an author at The University of Texas MD Anderson Cancer Center specializing in molecular oncology, cancer cell biology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	18
2	Pathology	1	1	18
3	Pharmacology	1	1	18
4	Cancer Cell Biology	1	1	18
5	Cancer Therapeutics	1	1	18

H. T. See

Publications

232

Citations

H-Index

Page 1

	Year	Citations
Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study Siriwan Tangjitgamol, Pedro T. Ramírez, Ci-Yuan Sun, International Journal of Gynecological Cancer	2005	54
Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance H. T. See, Ralph S. Freedman, Andrzej P. Kudelka, International Journal of Gynecological Cancer	2005	46
Combined adjuvant cisplatin and ifosfamide chemotherapy and radiotherapy for malignant mixed mullerian tumors of the uterus Limy Wong, H. T. See, Hoon Seng Khoo-Tan, International Journal of Gynecological Cancer	2006	22
Secondary leukemia after treatment with paclitaxel and carboplatin in a patient with recurrent ovarian cancer H. T. See, Daleen Thomas, Carlos Bueso-Ramos, International Journal of Gynecological Cancer	2006	20
Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance H. T. See, Ralph S. Freedman, A P Kudelka, International Journal of Gynecological Cancer	2005	20
Triple-negative metastatic/recurrent breast cancer: Treatment with paclitaxel/carboplatin combination chemotherapy John Chia, Peter Ang, H. T. See, Journal of Clinical Oncology Breast OncologyPaclitaxel/carboplatin Combination ChemotherapyMetastatic/recurrent TnbcMedicineCancer Management	2007	18
Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study Siriwan Tangjitgamol, Paulino Ramirez, Cheng‐Cao Sun, International Journal of Gynecological Cancer	2005	14
Third-line chemotherapy in platinum- and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients Siriwan Tangjitgamol, H. T. See, S. Manusirivithaya, International Journal of Gynecological Cancer	2004	13
Secondary leukemia after treatment with paclitaxel and carboplatin in a patient with recurrent ovarian cancer H. T. See, Deborah A. Thomas, Carlos Bueso-Ramos, International Journal of Gynecological Cancer	2006	13
Attitudes towards cancer survivors: a small survey. Hong Chen, Wen‐Hann Tan, Wan C. Tan, PubMed	2006	12

Page 1